COVID- 19 Risk Test Approved for Commercial Release
Filed with ASX · · 2 pages · English
Melbourne, Australia, [21] October 2020:“Company”, “GTG”), a diversified Genomics and AI driven preventative health businessMolecular diagnostics company Genetic provides an Technologies Ltd (ASX: GTG; NASDAQ: GENE, “Company”), provides the following update to theupdate to the market on the progress of theUS commercial availability of the Company’s COVID-19 market.Serious Disease Risk Test(‘COVID-
Genetic Technologies Limited on 6ix
Earlier from Genetic Technologies
- GTG signs 3-year US licence agreement for COVID risk test
- Pause in Trading
- 1H21 Half Year Results
- Genetic Technologies US$6.56 Million Capital Raising
- Genetic Technologies appoints Simon Morriss as CEO
Later from Genetic Technologies
- GTG COVID-19 Risk Test launched in USA
- US Patent Office Grants Foundational Pharmacogenomic Patent
- Genetic Technologies Acquires EasyDNA
- Genetic Technologies Investor Presentation and Webinar
- Completion of EasyDNA Acquisition set for global expansion
Follow Genetic Technologies into a list and get an email when it puts out news.
Follow Genetic Technologies